Company / R&D Expense
Gain Therapeutics, Inc. R&D Expense History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$11.5M
FY2024
5-year range
$2.3M / $11.5M
FY2021-FY2024
Trend
+37.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 3 consecutive years, from $2M in FY2021 to $12M in FY2024.
Based on SEC 10-K filings.
$12M in FY2024 with a 3-year CAGR of +72.1%.
Improved from $7M to $12M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +72.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s r&d expense has grown for 3 consecutive years.
- 3-year CAGR of +72.1%, indicating consistent growth.
- In FY2024, r&d expense increased 37.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $11.5M | +37.5% |
| FY2023 | $8.4M | +16.9% |
| FY2022 | $7.2M | +217.1% |
| FY2021 | $2.3M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026